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SUMMARY
Norovirus is the most frequently occurring cause of community-acquired acute gastroenteritis in 
people of all ages. It is also one of the most frequent causes of outbreaks in healthcare settings, 
affecting both long-term care facilities and acute care hospitals. Whereas norovirus gastroenteritis 
is typically mild and resolves without medical attention, healthcare-associated infections often 
affect vulnerable populations, resulting in severe infections and disruption of healthcare services. 
Globally, most norovirus outbreaks in hospitals and residential care institutions are associated with 
genogroup II type 4 (GII.4) strains. Recent data demonstrate that excess mortality occurs during 
outbreak periods in healthcare facilities. Nosocomial outbreaks can result in large economic and 
societal costs. Current control measures for norovirus are largely based on general infection 
control principles, and treatment is mainly supportive and non-specific. While neither vaccines nor 
antiviral agents are currently available, both are being developed with encouraging results.
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Introduction
Norovirus is the leading cause of community-acquired gastroenteritis in all age groups, 
being associated with 18% of all acute gastroenteritis cases globally.1 An estimated 19–21 
million cases of norovirus and nearly 800 resulting deaths occur in the USA each year.2 The 
high prevalence of norovirus in the community makes it difficult to prevent introduction into 
healthcare settings, including long-term care facilities and acute care hospitals, where 
infection can spread and result in severe illness. Surveillance data from high-income 
countries around the world consistently indicate that most norovirus outbreaks occur in 
healthcare facilities.3 Both acute care hospitals and long-term care facilities are affected. 
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From 1992 to 2000, ~40% of 1877 reported norovirus outbreaks in England andWales 
occurred in hospitals, with another 39% in residential care facilities.4 Similar findings have 
been reported elsewhere in Europe and in other high-income countries, where outbreaks in 
acute care and long-term care facilities are roughly equal in frequency.5–7 Reports of acute 
care outbreaks in the USA, however, are relatively infrequent, and >60% of all reported 
norovirus outbreaks in the USA occur in long-term care facilities such as nursing homes.8 
Though this discrepancy in rates of acute care norovirus outbreaks between the USA and 
other high-income countries may be the result of a lower incidence of acute care outbreaks 
in the USA, it may also signify substantial underreporting of such outbreaks. A recent 
survey of infection prevention personnel in US hospitals provides evidence for 
underreporting; norovirus was reported as the most frequent cause of outbreaks of hospital-
acquired infection, accounting for 18% of outbreaks and >65% of hospital unit closures.9 
Studies in Europe also have found evidence for significant underreporting of norovirus 
illness, including nosocomial infection.10,11
Biology and transmission characteristics
Noroviruses are positive-sense single-stranded RNA viruses that are both genetically and 
antigenically diverse.12 Human illness is predominantly caused by two genogroups (G) of 
norovirus, GI and GII, which consist of nine and 22 genotypes, respectively.13 Noroviruses 
have evolved several characteristics that facilitate transmission through human populations. 
The virus is transmitted primarily through the fecal-oral pathway; ingestion of as little as 
18–1000 viral particles can lead to infection.14,15 Recent analysis of volunteer studies 
suggests a higher ID50, but still supports the notion of a low infectious dose. In addition to 
direct person-to-person transmission, people may come into contact with norovirus through 
contaminated food, water, or aerosolized particles.16–18 Aerosolization of norovirus 
following vomiting can be particularly problematic, as norovirus particles can settle on 
surfaces and fomites and survive for long periods of time, and have been shown to withstand 
low levels of chlorine disinfection and temperatures ranging from freezing to 60°C.16,19–22 
A study of environmental samples from outbreak-affected hospital wards found GII 
norovirus on almost half of the swabs, including in dust and on surfaces.23 Once the virus is 
ingested, there is an incubation period of between 12 and 48 h, after which infected persons 
generally experience acute onset of symptoms of gastroenteritis, such as vomiting, 
diarrhoea, abdominal cramps, as well as systemic symptoms, including fever. However, 20–
30% of infected individuals may remain asymptomatic. 24 The dynamics of viral shedding 
can also facilitate norovirus transmission. Shedding can precede symptom onset in up to 
30% of those exposed to the virus, peaks around four days after exposure, and can continue 
for up to eight weeks.14,25 Viral particles are shed profusely in faeces, with between 105 and 
1010 viral copies per gram of stool, but can also be found in vomitus.25 Asymptomatic 
individuals may also shed norovirus, though the infectivity of shed particles is 
unknown. 14,25,26 Together, the long shedding period and large amount of virus shed per 
infected person contribute to environmental persistence of the virus and secondary attack 
rates of ≥30% among contacts of infected individuals.20
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Transmission and control in healthcare settings
Many of the same characteristics that promote community transmission are magnified in the 
healthcare setting. Whereas most community cases of norovirus resolve within 12–60 h and 
without medical attention, nosocomial outbreaks of norovirus largely affect vulnerable 
populations, including the institutionalized elderly and the immunocompromised.27 In such 
populations, typically mild infections may progress to more severe or prolonged illness.27–31 
Among vulnerable populations, symptoms of norovirus may last for between four and six 
days.32 However, chronic norovirus symptoms and shedding lasting for 15 months were 
described in an HIV-affected patient. 31 In addition to longer symptomatic periods, 
individuals in healthcare settings may shed for extended periods of time, acting as reservoirs 
for spread of the virus to other susceptible persons.32–34 Reports have detailed shedding 
periods ranging from 22 to 433 days in paediatric cancer patients.35
Nosocomial outbreaks of norovirus may result in severe patient outcomes. Whereas deaths 
caused by norovirus are rare in the community, individuals in healthcare facilities, 
particularly the elderly, are more likely to be hospitalized or die.36–40 Estimates from 
England, Wales, The Netherlands, and the USA suggest that norovirus constitutes a leading 
cause of gastroenteritis-associated deaths in those aged >65 years of age.36,37,41,42 Increases 
in the annual numbers of deaths have been observed in years in which novel GII.4 viruses 
emerged, and were recognized to cause global increases in cases. The widely circulating 
GII.4 noroviruses undergo antigenic changes to escape from population immunity, resulting 
in emergence of a new strain every two to four years.43–47 These novel strains have been 
associated with pandemics as well as with increased morbidity and mortality.40,45,46,48,49 
GII.4 noroviruses are particularly predominant in healthcare settings.5,7,21 Some of the 
strongest evidence that norovirus plays a causal role in deaths comes from a study of >400 
US nursing home outbreaks, where an 11% (95% CI: 5–18%) increase in all-cause mortality 
was observed during periods in which these institutions were experiencing outbreaks.50 A 
detailed outbreak investigation suggested that some excess mortality may be associated with 
drugs used frequently in the elderly.51
In addition to causing severe illness in hospitalized individuals, norovirus may also spread 
rapidly throughout facilities, leading to high attack rates. A recent study demonstrated that 
the average interval of time from the infection of one patient to another (i.e. the serial 
interval) was 1.86 days.52 This study also provided evidence that proximity (i.e. occupying a 
bed in the same bay as an infected patient) was a risk factor for infection in patients. Since 
nurses and other healthcare staff also work in close proximity to patients, the virus 
commonly affects staff working in outbreak wards. In one outbreak in a US tertiary care 
hospital, 105 healthcare workers in two separate units became ill, of whom 13 visited the 
emergency department or were hospitalized for their condition. 53 Given the high levels of 
contact in healthcare settings, defining the relative role of staff and patients, both 
symptomatic and asymptomatic, is a critical question for norovirus transmission. A 
modelling study of a series of outbreaks in Dutch hospitals suggests that symptomatic 
patients, rather than asymptomatic healthcare workers, are the main drivers of 
transmission.54
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Current prevention and control measures for norovirus aim to minimize the risk of 
introduction and transmission of the virus in healthcare settings.55,56 The recommendations 
for prevention and control are summarized in Box 1.57 One particularly controversial control 
measure is the closure of hospital wards or units to new admissions. This is a costly measure 
from an economic perspective and disruptive to the provision of healthcare services. The 
efficacy and costeffectiveness of ward closure remain a subject of debate, although there is 
some evidence suggesting that rapid implementation of control measures reduces the overall 
duration and final outbreak size.58
Box 1
Key infection control recommendations for the 
control of norovirus outbreaks in healthcare settingsa
Patient cohorting and isolation precautions
• Place patients with norovirus gastroenteritis on contact precautions for a minimum of 48 h after the 
resolution of symptoms.
• When symptomatic patients cannot be accommodated in single occupancy rooms, efforts should be 
made to cohort patients into separate groups (e.g. grouped among those who are symptomatic, 
exposed but asymptomatic, and unexposed).
• Minimize patient movements within a ward or unit during norovirus outbreaks.
• Symptomatic and recovering patients should not leave the patient care area unless it is for essential 
care or treatment.
• Consider suspending group activities.
• Healthcare personnel who have recovered from recent suspected norovirus infection associated 
with this outbreak may be best suited to care for exposed or symptomatic patients.
Hand hygiene
• Actively promote adherence to hand hygiene among healthcare personnel, patients, and visitors in 
patient care areas affected by outbreaks of norovirus gastroenteritis.
• During outbreaks, prioritize hand hygiene with soap and water after providing care or having 
contact with patients suspected or confirmed with norovirus gastroenteritis.
Personal protective equipment (PPE)
• If norovirus infection is suspected, individuals entering the patient care area should wear PPE 
according to contact and standard precautions (i.e. gowns and gloves, and among vomiting patients, 
face masks).
Environmental cleaning
• Perform routine cleaning and disinfection of frequently touched environmental surfaces.
• Increase the frequency of cleaning and disinfection of patient care areas and frequently touched 
surfaces during outbreaks of norovirus gastroenteritis.
• Clean and disinfect surfaces, starting from the areas with a lower likelihood of norovirus 
contamination, then to areas with greater likelihood.
• Use standard precautions for handling soiled patient-service items or linens, which includes the 
appropriate use of PPE.
• Consider changing privacy curtains routinely and upon patient discharge or transfer.
Patient transfer and ward closure
• Closure of wards to new admissions or transfers may be a measure to attenuate the magnitude of a 
norovirus outbreak.
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• Consider patient transfers only if receiving facilities are able to maintain contact precautions. 
During outbreaks, medically suitable individuals recovering from norovirus gastroenteritis can be 
discharged to their place of residence.
Personnel leave
• Exclude ill personnel from work for a minimum of 48 h after the resolution of symptoms. Once 
personnel return to work, strict adherence to hand hygiene must be maintained.
• Establish protocols for staff cohorting in the event of a norovirus outbreak.
• Exclude non-essential healthcare providers, students, and volunteers from working in areas 
experiencing outbreaks of norovirus.
Visitors
• Restrict non-essential visitors from affected areas during outbreaks.
• For those facilities where it is necessary to have continued visitation privileges, screen and exclude 
visitors with symptoms consistent with norovirus infection.
Diagnostics
• Submit stool specimens as early as possible during a suspected norovirus gastroenteritis outbreak 
and ideally from individuals during the acute phase of illness.
• In the absence of clinical laboratory diagnostics for norovirus, or in the case of delay in obtaining 
laboratory results, use Kaplan’s clinical and epidemiologic criteria to identify a norovirus 
gastroenteritis outbreak.
a
Adapted from MacCannell et al.57
Economic burden
Control measures such as exclusion of infected healthcare workers, patient isolation, and 
ward closures are intended to reduce viral transmission, but they may also lead to disruption 
of health services and contribute to the economic losses. The large number of affected 
healthcare workers in the previously described US tertiary care hospital outbreak led to 
staffing shortages and a restriction on new patient admissions. This single large outbreak 
was estimated to have resulted in more than $650,000 in lost revenue, staff wages, and 
cleaning expenses. 53 Hospitals in other countries have also experienced similarly 
substantial losses. An outbreak in a Swiss hospital cost $40,675 in additional diagnostic 
materials, increased need for healthcare, revenue loss, and sick leave.59 In this outbreak, 
patient bed closures were found to have contributed the most to incurred losses, costing 
roughly three times more than lost productivity costs from infected healthcare staff.59 
Nosocomial outbreaks of acute gastroenteritis have been estimated to cost the English 
National Health Service roughly $184 million annually.3
Progress in antiviral treatment and vaccine development
In recent years, improved understanding of the public health burden of norovirus infection 
and the accompanying costs have given impetus to the development of antiviral treatments 
and vaccines. There is currently no specific treatment for norovirus gastroenteritis; cases are 
managed with supportive therapy such as rehydration. Effective treatment is especially 
important for those who are immunocompromised, since they may have one or more 
comorbidities or may be recovering from a major procedure such as an organ transplant. 29 
Kambhampati et al. Page 5













In these individuals, large volumes of fluid loss and the inability to digest food may 
necessitate intravenously administered nutritional formulae.29 Antivirals such as favipiravir 
and ribavirin, which work by inhibiting viral entry and replication, have demonstrated 
activity against other RNA viruses as well as norovirus replicons.29,60 These treatment 
options have not been tested in humans. Moreover, the rapid kinetics of norovirus infection 
may limit the clinical utility of antivirals.
Though evidence suggests that there may be numerous potential benefits from norovirus 
vaccines, development has been impeded by technical limitations, most notably by the lack 
of a cell culture system. A norovirus vaccine could potentially decrease societal costs each 
year by up to $2.1 billion and prevent nearly 48,000 hospital admissions.61 However, there 
has been little success in culturing norovirus in vitro, so attenuated and inactivated vaccines 
cannot be created.62 Since the virus is only known to infect humans, there are no appropriate 
animal models available to evaluate immune response. Recently, however, one study 
reported a successful culture system for human norovirus. Researchers demonstrated that the 
GII.4 Sydney strain of norovirus infected human B cells in vitro in the presence of histo-
blood group antigens (HBGA) or HBGA-expressing bacteria.63 Although this recent 
achievement has not yet been replicated, the ability to grow norovirus in the laboratory 
would lead to critical developments including infectivity and neutralizing antibody assays. 
To date, norovirus vaccine development has largely been predicated on the ability to 
produce virus-like particles (VLPs), viral capsid structures made of self-assembling 
proteins.64–66 Although they lack a viral genome, VLPs mimic the native virus, and have 
successfully been used in vaccines for hepatitis B and human papillomavirus.67 Results from 
a multicentre trial of a monovalent VLP intranasal vaccine found that the vaccine reduced 
the frequency of norovirus gastroenteritis from 69% in recipients of the placebo to 37% in 
volunteers who received the vaccine.68 The success of the monovalent vaccine prompted the 
development of a bivalent injectable vaccine containing both GI.1 and GII.4 virus-like 
particles. The vaccine was found to be immunogenic and well tolerated by volunteers, and 
reduced the severity of illness in those who received the vaccine. 69,70 This vaccine is yet to 
be evaluated for safety or efficacy in a large Phase III trial. Other VLP-based vaccinations 
are also in development, including a trivalent GII.4/GI.3/ rotavirus VP6 product and a dry 
powder intranasal formulation. 71,72 An alternative vaccine, based on norovirus P particles 
expressed in an Escherichia coli system, contains only the protruding outer portion of the 
norovirus protein.73,74 When administered to mice, this vaccine candidate elicited effective 
humoral and cellular immune responses, and may elicit a stronger T-cell response in 
comparison to the two-dose intranasal VLP vaccine.74,75
There are several challenges in developing and licensing a norovirus vaccine, as well as in 
establishing recommendations for them. Noroviruses are genetically diverse, and frequently 
undergo antigenic drift, giving rise to new strains.76 Immunity to norovirus is of limited 
duration. Data from early human challenge studies suggested that immunity could last from 
two months to two years; subsequent studies demonstrated immunity of at least six 
months.77,78 Moreover, protection against one strain of norovirus may not preclude infection 
with another strain. In a study of volunteers who were challenged with three different 
strains, individuals were susceptible to antigenically distinct strains earlier than they were to 
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more closely related strains.79 Vaccines should aim to elicit some type of cross-reactive 
protection, and include consideration of potential novel strains during formulation.
Conclusions
While norovirus affects people of all ages and is exceedingly widespread in the community, 
much of the considerable health and economic burden is concentrated in healthcare-
associated outbreaks. It may be impossible to prevent every introduction of norovirus into 
healthcare facilities. Controlling transmission is also challenging, owing to the multiple 
routes of transmission, high infectiousness, and environmental stability of noroviruses. 
Current guidelines for prevention and control are largely based on sound infection control 
principles, but an evidence base for the efficacy of specific measures is lacking. Both 
observational and intervention studies should be undertaken to address this knowledge gap. 
In the future, a norovirus vaccine may become an important tool for control of disease in 
healthcare settings, but several challenges remain.
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